Stockscreener 앱 받기
8.01
8.83%
0.65
시장 영업 전:
7.77
-0.24
-3.00%
전일 마감가:
$7.36
열려 있는:
$7.71
하루 거래량:
127.15K
Relative Volume:
1.07
시가총액:
$29.50M
수익:
-
순이익/손실:
$-31.11M
주가수익비율:
-5.2353
EPS:
-1.53
순현금흐름:
$-28.18M
1주 성능:
+7.37%
1개월 성능:
+15.25%
6개월 성능:
-31.32%
1년 성능:
-46.42%
1일 변동 폭
$7.65
$8.15
1주일 범위
$6.955
$8.15
52주 변동 폭
$5.3495
$28.34
Tempest Therapeutics Inc Stock (TPST) Company Profile
명칭
Tempest Therapeutics Inc
전화
415-798-8589
주소
2000 SIERRA POINT PARKWAY, BRISBANE
TPST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
8.01 | 27.10M | 0 | -31.11M | -28.18M | -1.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-08 | 개시 | Jefferies | Buy |
Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스
Tempest Therapeutics Reports Q2 2025 Financial Results - TipRanks
Tempest Therapeutics Inc. stock chart pattern explainedShort Squeeze Opportunities with Indicators - Newser
What data driven models say about Tempest Therapeutics Inc.’s futureFree Entry and Exit Strategy Optimizer Tool - Newser
What makes Tempest Therapeutics Inc. stock price move sharplyYield Curve Outlook and Long-Term Implication Summary - Newser
Can machine learning forecast Tempest Therapeutics Inc. recoveryDividend Strategy Summary With 10-Year Outlook - Newser
Tempest Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65) - TipRanks
Technical analysis overview for Tempest Therapeutics Inc. stockFree Confirmed Setup With Expert Accuracy - Newser
Tempest Therapeutics: A Case Study in Operational Turnaround and Biotech Resilience - AInvest
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Tempest Secures Triple Regulatory Wins for Cancer Drug Amezalpat as Q2 Losses Narrow - Stock Titan
Is it too late to sell Tempest Therapeutics Inc.Pattern Recognition Tool for ROI Investors - Newser
Custom watchlist performance reports with Tempest Therapeutics Inc.Long-Term Growth Trend Summary With Confidence - Newser
Tempest Therapeutics Inc. stock outlook for YEARFree Smart Trade Plans With Risk Protection - Newser
Real time alert setup for Tempest Therapeutics Inc. performanceInvestment Life Cycle Planning Summary - Newser
Why Tempest Therapeutics Inc. stock attracts strong analyst attentionFree Step-by-Step Trade Signal Implementation - Newser
Quantitative breakdown of Tempest Therapeutics Inc. recent moveSupport and Resistance Zone Summary Chart - Newser
Published on: 2025-08-10 01:25:41 - Newser
What technical models suggest about Tempest Therapeutics Inc.’s comeback - Newser
Multi factor analysis applied to Tempest Therapeutics Inc.Short Term Gain Strategy with AI Logic - Newser
Tempest Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayROI Focused Setup Screener With Exit Markers - Newser
Published on: 2025-08-09 23:28:19 - Newser
How Tempest Therapeutics Inc. stock performs during market volatilityFree Chart Breakout Buy Signal Detection - Newser
Tempest Therapeutics Inc expected to post a loss of $2.60 a shareEarnings Preview - TradingView
Is Tempest Therapeutics Inc. stock bottoming outWeekly Hot Stocks Based on Volume Flow - Newser
Tempest Therapeutics (TPST) Expected to Announce Quarterly Earnings on Thursday - Defense World
Long term hold vs stop loss in Tempest Therapeutics Inc.Smart Forecast Signals from AI Models - Newser
How Interest Rate Changes Impact Tempest Therapeutics Inc. Stock PerformanceAI Trading Forecast Based on Big Data - Newser
Morpheus-Liver Study: A New Horizon in Advanced Liver Cancer Treatment - TipRanks
Tempest Therapeutics Inc (TPST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.02%
3.70%
자본화:
|
볼륨(24시간):